{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:18:32Z","timestamp":1778923112838,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed Incorporated","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41030-025-00324-z","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:58:35Z","timestamp":1763139515000},"page":"221-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare Resource Utilization in Refractory MACLD: Comparison of an Amikacin Liposome Inhalation Suspension (ALIS) Cohort with a Non-ALIS Cohort"],"prefix":"10.1007","volume":"12","author":[{"given":"Timothy R.","family":"Aksamit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Waweru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsie","family":"Divinagracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Markson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"2","key":"324_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","volume":"17","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008\u20132015. Ann Am Thorac Soc. 2020;17(2):178\u201385.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"324_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3201\/eid2303.161827","volume":"23","author":"J Adjemian","year":"2017","unstructured":"Adjemian J, Frankland TB, Daida YG, et al. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017;23(3):439\u201347.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"324_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3201\/eid1403.061143","volume":"14","author":"EE Bodle","year":"2008","unstructured":"Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis. 2008;14(3):390\u20136.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"324_CR4","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1086\/648443","volume":"49","author":"PM Cassidy","year":"2009","unstructured":"Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009;49(12):e124\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"324_CR5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ajic.2019.04.171","volume":"47","author":"E Klann","year":"2019","unstructured":"Klann E, Beal SG, Tremblay EE. Evaluating differences in tuberculosis and nontuberculous mycobacterial lung disease in Florida. Am J Infect Control. 2019;47(11):1324\u20138.","journal-title":"Am J Infect Control"},{"issue":"7","key":"324_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","volume":"182","author":"DR Prevots","year":"2010","unstructured":"Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"324_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2334-11-113","volume":"11","author":"G Satyanarayana","year":"2011","unstructured":"Satyanarayana G, Heysell SK, Scully KW, Houpt ER. Mycobacterial infections in a large Virginia hospital, 2001\u20132009. BMC Infect Dis. 2011;11:113.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"324_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1\u201336.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"324_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"324_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","volume":"153","author":"R Diel","year":"2018","unstructured":"Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018;153(4):888\u2013921.","journal-title":"Chest"},{"key":"324_CR11","unstructured":"Arikayce. Prescribing information. Insmed; 2025. https:\/\/www.arikayce.com\/pdf\/full_prescribing_information.pdf. Accessed Mar 10, 2025."},{"key":"324_CR12","unstructured":"US Food & Drug Administration. FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation; 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibacterial-drug-treat-serious-lung-disease-using-novel-pathway-spur-innovation. Accessed Mar 27, 2025."},{"issue":"Suppl 4","key":"324_CR13","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1093\/infdis\/jiaa354","volume":"222","author":"CL Daley","year":"2020","unstructured":"Daley CL, Winthrop KL. Mycobacterium avium complex: addressing gaps in diagnosis and management. J Infect Dis. 2020;222(Suppl 4):S199-s211.","journal-title":"J Infect Dis"},{"key":"324_CR14","unstructured":"Merative, MarketScan for life sciences researchers, https:\/\/www.merative.com\/documents\/marketscan-for-life-sciences-researchers. Accessed Apr 29, 2025."},{"issue":"2","key":"324_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.36469\/jheor.2023.87538","volume":"10","author":"O Baser","year":"2023","unstructured":"Baser O, Samayoa G, Yapar N, Baser E, Mete F. Use of open claims vs closed claims in health outcomes research. J Health Econ Outcomes Res. 2023;10(2):44\u201352.","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"324_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12890-022-02257-8","volume":"22","author":"T Aksamit","year":"2022","unstructured":"Aksamit T, Wu J, Hassan M, Achter E, Chatterjee A. Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings. BMC Pulm Med. 2022;22(1):461.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"324_CR17","first-page":"964","volume":"24","author":"TK Marras","year":"2018","unstructured":"Marras TK, Mirsaeidi M, Chou E, et al. Health care utilization and expenditures following diagnosis of nontuberculous mycobacterial lung disease in the United States. J Manag Care Spec Pharm. 2018;24(10):964\u201374.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"324_CR18","doi-asserted-by":"publisher","first-page":"A768","DOI":"10.1016\/j.chest.2023.07.568","volume":"164","author":"KL Winthrop","year":"2023","unstructured":"Winthrop KL, Wang P, Lucci M, Welch E, Shah B, Hassan M. Treatment patterns and health care resource utilization among patients with potentially treatment-refractory mycobacterium avium complex lung diesease in the United States. Chest. 2023;164(4):A768\u20139.","journal-title":"Chest"},{"issue":"5","key":"324_CR19","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.02281-12","volume":"57","author":"WJ Koh","year":"2013","unstructured":"Koh WJ, Hong G, Kim SY, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57(5):2281\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"324_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108220","volume":"246","author":"TR Aksamit","year":"2025","unstructured":"Aksamit TR, Choate R, Mannino DM, Brunton AE, Wang P, Hassan M. Natural history and burden of refractory Mycobacterium avium complex pulmonary disease: insights from the US Bronchiectasis and Nontuberculous Mycobacterial Research Registry. Respir Med. 2025;246:108220.","journal-title":"Respir Med"},{"key":"324_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","volume":"3","author":"Z Bursac","year":"2008","unstructured":"Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.","journal-title":"Source Code Biol Med"},{"issue":"2","key":"324_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4172\/2161-1165.1000227","volume":"6","author":"KP Vatcheva","year":"2016","unstructured":"Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology (Sunnyvale). 2016;6(2):227.","journal-title":"Epidemiology (Sunnyvale)"},{"issue":"1","key":"324_CR23","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1038\/s41467-022-33686-y","volume":"13","author":"K Cassell","year":"2022","unstructured":"Cassell K, Zipfel CM, Bansal S, Weinberger DM. Trends in non-COVID-19\u00a0hospitalizations prior to and during the COVID-19 pandemic period, United States, 2017\u20132021. Nat Commun. 2022;13(1):5930.","journal-title":"Nat Commun"},{"issue":"1","key":"324_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/infdis\/168.1.112","volume":"168","author":"MA Jacobson","year":"1993","unstructured":"Jacobson MA, Yajko D, Northfelt D, et al. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis. 1993;168(1):112\u20139.","journal-title":"J Infect Dis"},{"key":"324_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40780-015-0025-4","volume":"1","author":"H Shimomura","year":"2015","unstructured":"Shimomura H, Ono A, Imanaka K, et al. Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease. J Pharm Health Care Sci. 2015;1:24.","journal-title":"J Pharm Health Care Sci"},{"issue":"4","key":"324_CR26","doi-asserted-by":"publisher","first-page":"A1036","DOI":"10.1016\/j.chest.2024.06.688","volume":"166","author":"KL Winthrop","year":"2024","unstructured":"Winthrop KL, Waweru C, Wang P, Welch E, Markson L. Longer use of amikacin liposome inhalation suspension during first 12\u00a0months associated with lower risk of hospitalizations and emergency room visits: a claims analysis. Chest. 2024;166(4):A1036\u20138.","journal-title":"Chest"},{"issue":"12","key":"324_CR27","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559\u201369.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"324_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw147","volume":"3","author":"K Fujita","year":"2016","unstructured":"Fujita K, Fujita M, Ito Y, et al. Preliminary evaluation of a sitafloxacin-containing regimen for relapsed or refractory pulmonary Mycobacterium avium complex disease. Open Forum Infect Dis. 2016;3(3):ofw147.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"324_CR29","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"324_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2014-000050","volume":"1","author":"K Fujita","year":"2014","unstructured":"Fujita K, Ito Y, Hirai T, et al. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res. 2014;1(1):e000050.","journal-title":"BMJ Open Respir Res"},{"key":"324_CR31","unstructured":"Novartis. NCT04334070 Lamprene Multiple Patient Program. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT04334070?tab=table.  Accessed Mar 20, 2025."}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00324-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:31:32Z","timestamp":1773667892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00324-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00324-z","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Timothy Aksamit was involved in clinical trial design and participation with AstraZeneca, Insmed Incorporated, Johnson & Johnson, Redhill Biopharma, Spero Therapeutics, and Zambon. He has worked with Hillrom and RespirTech and served as medical director of Bronchiectasis and NTM 360 for the COPD Foundation. No personal or research monies were received. All support has gone to the Mayo Foundation for medical research and education. Catherine Waweru, Ping Wang, and Leona Markson are employees and shareholders of Insmed Incorporated. Emily Welch is an employee of Panalgo, a paid consultant for Insmed Incorporated. Elsie Divinagracia was an employee of Panalgo, a paid consultant for Insmed Incorporated, at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No patients were enrolled, and no human tissue samples were collected or used. Because the study did not involve the collection, use, or transmittal of individually identifiable data, institutional review board approval was not\u00a0required, and the study was considered exempt according to 45CFR46.101(b)(4): Existing Data and Specimens\u2014No Identifiers.\u00a0Ethics approval was not required because this was a retrospective database study using deidentified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}